|
Mutation Information
|
Mutation Site
|
K103N |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.Y181C+rt.K103N |
|
Relevant Drug
|
doravirine (DOR) |
Literature Information
|
PubMed PMID
|
32816220
|
|
Published Year
|
2020 |
|
Journal
|
Clinical drug investigation |
|
Title
|
Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. |
|
Author
|
Khalilieh S,Yee KL,Sanchez R,Stoch SA,Wenning L,Iwamoto M |
|
Evidence
|
Even at this decreased C24, doravirine plasma concentrations exceed the pharmacokinetic target of 78 nM, which is greater than 6-fold the in vitro IC50 for inhibition of wild-type virus, and exceeds IC50 values for common single resistance mutations (K103N, Y181C, G190A), and of the K103N/Y181C double mutant. Steady-state AUC was selected as the exposure measure from which to judge clinical relevance from a safety perspective, as this parameter is an integration of concentrations over the 24-h dosing interval in which individuals are exposed to doravirine at steady state.
|
|
|
HIV Mutation Detail Information